Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

PACMAN European multicenter clinical study of over 300 patients begins at up to 50 centers in nine countries, the company announces April 25. The study will evaluate treatment of patients with chronic heart failure using either the Contak TR or CD cardiac resynchronization devices. The trial complements the company's COMPANION study, which commenced in the U.S. in February. COMPANION will collect data on more than 2,000 patients enrolled in up to 80 U.S. centers. Both studies will look at exercise performance, length and frequency of hospitalization and quality of life. The U.S. study also will evaluate survival rates
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel